Efficacy of Acyclovir in Pityriasis rosea

Efficacy of Acyclovir in Pityriasis rosea, a double blind randomized controlled trial in a tertiary care hospital in Pakistan.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210823052264N2

Enrollment

Registered

2023-02-06

Start date

2023-02-10

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pityriasis rosea. Pityriasis rosea

Interventions

Intervention 1: Intervention group: In group “A” patients were treated with oral acyclovir 800mg 5 times/day for a duration of 7 days. Intervention 2: Intervention group: In group “B” patients were t

Eligibility

Sex/Gender

All

Age

12 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients presenting with pityriasis rosea within first week of eruption of papulosquamous rash. Either gender between Age 12-70 years.

Exclusion criteria

Exclusion criteria: Positive venereal disease research laboratory (VDRL) test. Females with pregnancy or lactation. Patients who have taken any other specific treatment for PR in last 01 week. Patients with any cause of immunosuppression like chronic renal failure, diabetes mellitus, HIV positive and malignancy etc.

Design outcomes

Primary

Measure	Time frame
Clinical Response based on clearance of lesions. Timepoint: Patients in both the groups were evaluated clinically on 7th and 14th day of treatment. Method of measurement: Clinical Response Evaluation.	—

Countries

Pakistan

Contacts

Public ContactNajia Ahmed

PNS shifa

najiaomer@yahoo.com+92 81 2864092

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026